These highlights do not include all the information needed to use REZVOGLAR safely and effectively. See full prescribing information for REZVOGLAR.REZVOGLAR (insulin glargine-aglr) injection, for subcutaneous use Initial U.S. Approval: 2021 REZVOGLAR (insulin glargine-aglr) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of Rezvoglar has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to LANTUS (insulin glargine)

Patient Home

Welcome to Health Vidya. Discover trusted care and your own health — all in one place.

These highlights do not include all the information needed to use REZVOGLAR safely and effectively. See full prescribing information for REZVOGLAR.REZVOGLAR (insulin glargine-aglr) injection, for subcutaneous use Initial U.S. Approval: 2021 REZVOGLAR (insulin glargine-aglr) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of Rezvoglar has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to LANTUS (insulin glargine)

Medication label

Why this: Advisory · dailymed-prescription

REZVOGLAR™ is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use REZVOGLAR is not recommended for the treatment of diabetic ketoacidosis.

generic_name: insulin glargine-aglr
product_names: Insulin glargine-aglr
ndc: 0002-8980, 0002-8980-01, 0002-8980-05
group: drugs
license: us-gov-pd
attribution: Courtesy of the National Library of Medicine
reviewed: 2026-09-18
language: en